Errata - English

In B: Change
It meets the requirements in the test Viscosity—Capillary Methods <911>, Viscosity—Rotational Methods <912>, and Viscosity—Rolling Ball Method <913>.
to:
It meets the requirements in the test Viscosity—Capillary Methods <911>, Viscosity—Rotational Methods <912>, or Viscosity—Rolling Ball Method <913>.

In Analysis: Change
r_C = peak response of ceftiofur from the Sample solution (mg/mL)
r_A = sum of the responses of all peaks that elute after ceftiofur from the Sample solution (mg/mL)
to:
r_C = peak response of ceftiofur from the Sample solution
r_A = sum of the responses of all peaks that elute after ceftiofur from the Sample solution

In Analysis: Change
r_C = peak response of ceftiofur from the Sample solution (mg/mL)
r_A = sum of the responses of all peaks that elute after ceftiofur from the Sample solution (mg/mL)
to:
r_C = peak response of ceftiofur from the Sample solution
r_A = sum of the responses of all peaks that elute after ceftiofur from the Sample solution

In USP Cetirizine Related Compound A RS: Change
2-(2-{4-[(4-Chlorophenyl)phenylmethyl]piperazin-1-yl}ethoxy)acetic acid, ethyl ester dihydrochloride.
C₂₃H₂₉ClN₂O₃ · 2HCl 489.86
to:
(RS)-2-[2-[4-[(4-Chlorophenyl)phenylmethyl]piperazin-1-yl]ethoxy]acetic acid ethyl ester oxalate.
C₂₃H₂₉ClN₂O₃ · C₂H₂O₄ 506.98

In USP Clomiphene Related Compound A RS: Change
(E,Z)-2-[4-(1,2-Diphenylethyl)phenoxy]-N,N-diethylethanamine hydrochloride.
to:
(E,Z)-2-[4-(1,2-Diphenylvinyl)phenoxy]-N,N-diethylethanamine hydrochloride.
Also known as (E,Z)-2-[4-(1,2-Diphenylethenyl)phenoxy]-N,N-diethylethanamine hydrochloride.

In Absorptivity: Change
The absorptivity of the Sample solution at 445 nm is NLT 95.0% and NMT 103.0% that of the Standard solution.
to:
The absorptivity, calculated on the dried basis, of the Sample solution at 445 nm is NLT 95.0% and NMT 103.0% that of the Standard solution.

Change
C_S = concentration of USP Diphenhydramine Hydrochloride RS and USP Ibuprofen RS in the Standard solution (mg/mL)
to:
C_S = concentration of USP Diphenhydramine Hydrochloride RS or USP Ibuprofen RS in the Standard solution (mg/mL)

In the second equation in Analysis: Change
Result = (R_L − P_B)/(P_A − P_B)
to:
Result = (R_L − P_B)/(P_A − P_B) × 100

In Aflatoxin standard solution: Change
ε = molecular absorptivity
to:
ε = molar absorptivity
AND
in paragraph 2 of Aflatoxin standard solution: Change
transfer an accurate volume of each aflatoxin standard stock solution
to:
transfer an accurate volume of each aflatoxin stock solution

In Peptone diluent: Change
Dispense into sterile containers as needed for preparing samples. Trace mineral solution. Prepare a solution containing
to:
Dispense into sterile containers as needed for preparing samples.
Trace mineral solution: Prepare a solution containing

In Peptone diluent: Change
Dispense into sterile containers as needed for preparing samples. Trace mineral solution. Prepare a solution containing
to:
Dispense into sterile containers as needed for preparing samples.
Trace mineral solution: Prepare a solution containing

In USP Telmisartan Related Compound A RS: Change
1,7’-Dimethyl-2’-propyl-1H,3’H-2,5’-bibenzo[d]imidazole.
C₁₉H₂₀N₄ 304.39
to:
1,7’-Dimethyl-2’-propyl-1H,3’H-2,5’-bibenzo[d]imidazole monohydrate.
C₁₉H₂₀N₄ ∙ H₂O 322.41

In USP Sumatriptan Succinate Related Impurities RS: Change
Mixture of sumatriptan succinate, [3-[2-(methylamino) ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide maleate salt, sumatriptan succinate related compound C, [3-[2-(dimethylamino-N-oxide)ethyl]-1H-indol- 5-yl]-N-methylmethanesulfonamide, and [3-[2-(aminoethyl)]-1H-indol-5-yl]-N-methyl methanesulfonamide.
to:
Mixture of sumatriptan succinate, [3-[2-(methylamino)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide, sumatriptan succinate related compound C, [3-[2-(dimethylamino-N-oxide)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide, and [3-[2-(aminoethyl)]-1H-indol-5-yl]-N-methyl methanesulfonamide.

In USP Sumatriptan Succinate Related Impurities RS: Change
Mixture of sumatriptan succinate, [3-[2-(methylamino) ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide maleate salt, sumatriptan succinate related compound C, [3-[2-(dimethylamino-N-oxide)ethyl]-1H-indol- 5-yl]-N-methylmethanesulfonamide, and [3-[2-(aminoethyl)]-1H-indol-5-yl]-N-methyl methanesulfonamide.
to:
Mixture of sumatriptan succinate, [3-[2-(methylamino)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide, sumatriptan succinate related compound C, [3-[2-(dimethylamino-N-oxide)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide, and [3-[2-(aminoethyl)]-1H-indol-5-yl]-N-methyl methanesulfonamide.

Change
Each mL of 0.1 N perchloric acid is equivalent to 7.953 mg of C₄H₁₀N₂ · 2HCl.
to:
Each mL of 0.1 N perchloric acid is equivalent to 9.207 mg of C₄H₁₀N₂ · H₃PO₄.

In USP Atorvastatin Related Compound A RS: Change
Desfluoro impurity, or (3R,5R)-7-[3-(phenylcarbamoyl)-2-isopropyl-4,5-diphenyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid, calcium salt.
to:
Calcium (3R,5R)-7-[2-isopropyl-4,5-diphenyl-3-(phenylcarbamoyl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoate (1:2);
Also known as Desfluoro impurity, or (3R,5R)-7-[3-(phenylcarbamoyl)-2-isopropyl-4,5-diphenyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid, calcium salt.

In Column: Change
4.6-mm × 15-cm; 5-µm packing L7. [Note—Conditioning of the Column with Solution A and Solution B ^▲(90:10)_▲ (ERR 1-Mar-2019) for about 30 min is recommended prior to use.]
to:
4.6-mm × 15-cm; 5-µm packing L7

In Row 2 of Column 3 of Table 4: Change
0.014^▲/0.028_{▲2S (USP41)}
to:
0.014
AND
In Row 3 of Column 3 of Table 4: Change
0.014
to:
0.014/0.028
AND
In Chromatographic system/Column: Change
4.6-mm × 15-cm; 5-µm packing L7. [Note—Conditioning of the Column with Solution A and Solution B (80:20) for NLT 20 min is recommended prior to use.]
to:
4.6-mm × 15-cm; 5-µm packing L7

In the second variable definition list in Analysis: Change
V_S = volume of the Sample solution withdrawn at each time point, i
to:
V_S = volume of the Sample solution withdrawn at each time point, i (mL)

In USP Levalbuterol Related Compound D RS: Change
5-{2-[(1,1-Dimethylethyl)amino]-1-hydroxyethyl}-2-hydroxy-benzaldehyde.
C₁₃H₁₉NO₃ 237.29
^▲[NOTE—This may be available as the sulfate salt (2:1).]_{▲ (USP 1-May-2019)}
to:
5-[2-(tert-Butylamino)-1-hydroxyethyl]-2-hydroxybenzaldehyde sulfate (2:1) (salt);
Also known as 5-[2-{(1,1-Dimethylethyl)amino}-1-hydroxyethyl]-2-hydroxy-benzaldehyde sulfate (2:1).
(C₁₃H₁₉NO₃)₂ · H₂SO₄ 572.67

In Mobile phase: Change
^▲Acetonitrile, methanol, and acetic acid (50:50). To each liter of the solution add 3 mL of acetic acid and 1 mL of triethylamine._{▲ (USP 1-May-2019)}
to:
Acetonitrile and methanol (50:50). To each liter of the solution add 3 mL of acetic acid and 1 mL of triethylamine.

In USP Levalbuterol Related Compound D RS: Change
5-[2-{(1,1-Dimethylethyl)amino}-1-hydroxyethyl]-2-hydroxy-benzaldehyde;
Also known as 5-[2-{(1,1-Dimethylethyl)amino}methyl]-4-hydroxy-3-(methoxymethyl)-benzenemethanol.
C₁₃H₁₉NO₃ 237.29
[NOTE: This Reference Standard is available as the benzesulfonic acid salt.]
to:
5-[2-(tert-Butylamino)-1-hydroxyethyl]-2-hydroxybenzaldehyde sulfate (2:1) (salt);
Also known as 5-[2-{(1,1-Dimethylethyl)amino}-1-hydroxyethyl]-2-hydroxy-benzaldehyde sulfate (2:1).
(C₁₃H₁₉NO₃)₂ · H₂SO₄ 572.67

In 10.2 Algebra Method/10.2.1 Calculating by using the algebra method/Examples—Algebra method:
In example 2, in equations 1, 2, 3, and 4 in all instances: Change
C_s
to:
Q_s
AND
In example 2, in equation 5: Change
C_w
to:
Q_w